OnabotulinumtoxinA as Part of a Multimodal Program to Treat Vaginismus

This pilot study evaluated the efficacy and safety of intravaginal injection of onabotulinumtoxinA (Botox) with bupivacaine and progressive dilation under anesthesia along with post‐treatment counseling and support in the treatment of vaginismus. At baseline, all patients had failed some form of prior treatment. Following treatment, 90.3% of patients achieved pain‐free intercourse at a median of 3.5 weeks. This multimodal program, which treats both the physical and psychologic manifestations of vaginismus, appears to be safe and effective with no adverse events and no recurrence in this cohort during at least 1‐year follow‐up. Additional investigation in larger, placebo‐controlled clinical trials is indicated.
Source: Journal of Applied Biobehavioral Research - Category: Psychiatry & Psychology Authors: Tags: Original Article Source Type: research